OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination With Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to Anti-PD-1 Treatment

This global, open-label single-arm trial evaluated TAVO™, OncoSec’s proprietary IL-12 encoding plasmid delivered by intratumoral electroporation, in combination with pembrolizumab in patients with unresectable or metastatic (Stage III/IV) melanoma.